Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Ovarian cancer is one of those. Ovarian cancer starts in the ovaries, which are two small glands located on either side of ...

Corcept Therapeutics (NasdaqCM:CORT) saw a remarkable 36% increase in its share price in the last quarter, driven by several key developments. The company's significant announcement on March 31, ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Black and American Indian patients are less likely to have elevated CA-125 levels compared with White patients.

Real Housewives of Beverly Hills alum Teddi Mellencamp shared an update on the side effects of her cancer treatments, less ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...